semaglutide and general anesthesia New therapeutic agents for type 2 diabetes: anaesthetic considerations. A narrative review GLP-1 Side Effects and Semaglutide:

For compounding pharmacies or physicians that have been compounding semaglutide products during the shortage, the FDA has set clear deadlines for ceasing general semaglutide compounding practices: State-licensed pharmacies or physicians compounding semaglutide under Section 503A of the FD&C Act must stop compounding, distributing, or dispensing semaglutide injections that are essentially copies of an FDA-approved product by April 22, 2025

The figure printed on each batch's Certificate of Analysis is the actual value recorded in the laboratory, not a marketing claim

For people with Hashimotos or hypothyroidism, GLP-1 drugs may offer direct benefits, especially in weight management, metabolic health, reducing inflammation, and improving some symptoms of hypothyroidism: Weight loss Many people with hypothyroidism or Hashimotos struggle with weight gain due to a slowed metabolism

As was seen in prior studies 6,7,9,16 , while the vast majority of participants receiving semaglutide 2.4 mg had lost weight at the end of the STEP 5 study, a small proportion of participants experienced weight gain

American Journal of Physiology-Endocrinology and Metabolism , 282 , 474-482